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The  primary  objective  of this  investigation  was  to assess  whether  the  AS04-adjuvanted  herpes  sim-
plex  virus  (HSV)  glycoprotein  D  candidate  prophylactic  vaccine  against  genital  herpes  disease  increases
the risk  of  spontaneous  abortion  associated  with  pregnancy  conceived  within  the  vaccination  exposure
window  (vaccine  dose  received  within  the  period  starting  60 days  before  and  ending  20  weeks  post-
conception  day).  We  performed  a  meta-analysis  of  studies  designed  as part  of the  clinical  development
program  for  this  vaccine,  to  examine  the  relative  risk  of  abortion  (spontaneous  or  elective)  associated
with  unintended  vaccination  exposure  during  pregnancy.  Nineteen  studies,  completed  before  September
2010,  were  eligible;  5 matched  the  inclusion  criteria  for this  analysis  (presence  of a control  arm  and  at
least  one  adverse  pregnancy  outcome  reported).  All  vaccinated  women  (N = 19,727)  were included,  of
whom 660  reported  a pregnancy  during  the  study  period.  Overall,  13.3%  of pregnancies  in  the  HSV  vac-
cine  group  and  11.0%  in  the  control  group  resulted  in  spontaneous  abortion;  24.2%  and  20.0%  resulted
in  elective  abortion.  Among  180  women  with  a ﬁrst  pregnancy  conceived  in the  vaccination  exposure
window,  16.7%  (HSV  vaccine)  and  9.5%  (control)  had  a spontaneous  abortion  and  38.5%  and  33.3%,  elec-
tive abortion.  The  relative  risk for spontaneous  abortion  associated  with  vaccine  exposure  during  the risk
period for  abortion  in the  course  of  pregnancy  was  1.7  (95%  CI: 0.7–4.6).  For  all  women  receiving  HSV
vaccine,  this  relative  risk  was  1.3 (95%  CI: 0.8–2.1).  The  corresponding  relative  risks  for  elective  abortion
were  1.2  (95%  CI: 0.7–2.0)  and  1.3 (95%  CI: 0.9–1.8).  There  was  no apparent  relationship  to dosing  and  no
difference  between  groups  in gestational  age  at the  time  of  spontaneous  or elective  abortion.  In  conclu-
sion  there  is  no  statistical  evidence  that  the  investigational  HSV  vaccine  increased  the risk  of  spontaneous
or  elective  abortion.
. Introduction
In trials evaluating vaccination against sexually transmitted dis-
ases, such as those related to herpes simplex virus (HSV) or human
apilloma virus (HPV), the target population often includes women
f childbearing age. Even with the stringent precautions that are
lways put in place to avoid pregnancies in clinical trials, there
s nonetheless the potential for participants to become pregnant
uring the vaccination period, resulting in a potential risk of unin-
entional exposure to the study vaccine. Only limited data are
vailable to assess this risk. Indeed, vaccination is generally dis-
ontinued for women who become pregnant during a study, and
Abbreviations: RR, relative risk; LMP, last menstrual period; EDC, estimated date
f  conception; EDD, estimated date of delivery; CI, conﬁdence intervals.
 Available at: http://www.gsk-clinicalstudyregister.com/; ID: HSV meta-analysis.
∗ Corresponding author at: GlaxoSmithKline Vaccines, Avenue Fleming 20, B-
300 Wavre, Belgium. Tel.: +32 10 85 48 32.
E-mail address: fernanda.tavares@gsk.com (F. Tavares).
264-410X © 2013 Elsevier Ltd.  
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Open access under CC BY-NC-ND license.© 2013 Elsevier Ltd. 
no additional immunizations are administered to these women.
Furthermore, unless the vaccine is speciﬁcally designed for mater-
nal immunization, clinical studies designed to evaluate pregnancy
outcomes would not be included in the vaccine development pro-
gram. Still, for any licensed vaccine, the magnitude of any increased
risk of miscarriage and of the number of pregnancies at risk are
important factors in personal and public health decisions regarding
vaccination.
In this context, a meta-analysis was performed on studies from
the GlaxoSmithKline Vaccines (GSK) HSV vaccine clinical devel-
opment program, in order to evaluate the potential relative risk
(RR) for abortion (spontaneous or elective) associated with HSV
vaccination.
2. Material and methods
Open access under CC BY-NC-ND license.2.1. Eligibility criteria
All interventional GSK-sponsored studies in the HSV vac-
cine prophylactic clinical development program that were
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ompleted before September 2010 were eligible for inclusion in
he meta-analysis. Data from all females who received either the
nvestigational AS04-adjuvanted herpes simplex virus (HSV) gly-
oprotein D candidate prophylactic vaccine against genital herpes
isease (HSV vaccine) or a control vaccine in eligible studies were
ncluded. GSK study numbers for the 19 eligible studies were
he following: HPV-001 (208141/001 NCT00698893), HSV-002
208141/002, NCT00697567), HSV-005 (208141/005), HSV-006
208141/006), HSV-007 (208141/007), HSV-014 (208141/014),
SV-015 (208141/015, NCT00698490), HSV-016 (208141/016,
CT00698568), HSV-017 (208141/017, NCT00699764), HSV-019
208141/019), HSV-023 (208141/023), HSV-024 (208141/024),
SV-026 (208141/026), HSV-037 (208141/037), HSV-038
208141/038), HSV-039 (208141/039, NCT00057330), HSV-040
208141/040, NCT00224484), HSV-041 (208141/041), HSV-042
208141/042, NCT00224471). Protocol summaries can be obtained
rom http://www.gsk-clinicalstudyregister.com/. For the present
eta-analysis, the study ID is ‘HSV meta analyses’.
Studies had to meet the following criteria for inclusion in the
eta-analysis of spontaneous or elective abortions: the presence of
 control group in the study; the presence of at least one pregnancy
utcome of interest, i.e. spontaneous or elective abortion with or
ithout apparent congenital anomaly.
The data lock point for the analysis of pregnancy outcome from
he HSV program was 27 October 2010. All women of childbearing
otential enrolled in the HSV vaccine program were advised to use
n effective birth control method during the entire study period
nd 2 months after the completion of the vaccination series. They
ere tested for pregnancy with urine kits, immediately prior to
ach vaccination. The observation period began immediately after
accination.
.2. Cohorts analyzed
All women who received at least one vaccine dose in the selected
tudies (total vaccinated cohort) were included. Men  enrolled in 3
f the studies (HSV-007, -016 and -017) were not included. The
accines received were either the investigational HSV vaccine or
 control product (hepatitis A vaccine [HAV] (HavrixTM, GSK Vac-
ines), placebo or AS04 adjuvant system alone used as a control,
epending on the selected study).
.3. Ethics
All studies were conducted in accordance with the 1996 version
f the Declaration of Helsinki and with the International Conference
n Harmonization (ICH) Good Clinical Practice guidelines.
Study protocols were approved by the Institutional Review
oard of the institutions taking part and/or local ethics committees.
ritten informed consent was obtained from all subjects prior to
he performance of any study-speciﬁc procedures.
.4. Statistical analyses
The RR estimate and 95% conﬁdence intervals (CIs) were com-
uted using the exact conditional likelihood approach stratiﬁed for
he study effect (Proc StatXact4 for SAS Users, 1999) [3].
.5. Endpoints
The primary endpoint was to evaluate the risk of spontaneous
bortion associated with pregnancy conceived within the vaccina-
ion exposure window.
Secondary endpoints were: to evaluate the risk of elective abor-
ion associated with pregnancy conceived within the vaccination
xposure window, or any spontaneous or elective abortion.1 (2013) 1759– 1764
Only the ﬁrst reported pregnancy was  considered for subjects
who became pregnant more than once during the follow-up period
of the study (23 subjects).
According to international consensus, the gestational age is
measured from the ﬁrst day of the last menstrual period (LMP).
The pregnancy onset date or estimated date of conception (EDC) is
deﬁned as the date of LMP  +14 days. In case LMP  was unknown,
the EDC was calculated as the estimated date of delivery (EDD) by
ultrasound minus 266 days. The vaccination exposure window was
considered unknown if both the LMP  and the EDD were unknown,
or it could not be determined based on available parameters
obtained from the pregnancy report (e.g. ultrasound examination
or clinical assessment of the newborn).
Spontaneous abortion is deﬁned as the termination of a
pregnancy without human interference prior to 20 weeks post-
conception day (or 22 weeks of gestation) [6].  Elective abortion is
deﬁned as the induced termination of a pregnancy due to personal
choice or medical reasons prior to 20 weeks post-conception day
(or 22 weeks of gestation).
A pregnancy was considered to be in the vaccination exposure
window if a vaccine dose was received within a period starting 60
days before and ending 20 weeks post-conception day.
3. Results
3.1. Study selection for the meta-analysis
Nineteen GSK-sponsored interventional studies conducted as
part of the HSV vaccine development program and completed
before September 2010 were screened for inclusion in the meta-
analysis. Five of these met  the conditions required for evaluation
of the RR of the adverse pregnancy outcomes of interest (Table 1).
Study name abbreviations for the selected studies were as follows:
HSV-007, HSV-016, HSV-017, HSV-039 and HSV-040. In line with
the nature of this analysis, only data from female participants were
included. Women  who  received the candidate HSV vaccine were
included in the HSV vaccine group. The control group included
women who  received AS04 adjuvant alone (study HSV-007) or
placebo control (studies HSV-016, HSV-017 and HSV-040), or who
received the active comparator HAV (studies HSV-039 and HSV-
040).
3.2. Study characteristics
In the 5 selected trials, 19,727 women (10,964 in the pooled
HSV vaccine groups and 8763 in the control groups) were vacci-
nated and thus were included in the meta-analysis. Of the total
subjects included in the meta-analysis, the largest single group,
8323 women, came from the HSV-039 efﬁcacy study. The numbers
of women  vaccinated, reported pregnancies, and pregnancy out-
comes for each study included in analysis are shown in Table 1. For
the 19,727 women who received at least one vaccine dose during
the studies, the mean age was  23.6 ± 10.3 years in the HSV vaccine
group and 22.0 ± 9.3 years in the control group (age range: 10–80
years). The majority (86%) of women  were of white/caucasian
heritage in both groups. Six hundred and sixty women became
pregnant during the study period (368 in the HSV vaccine group
and 292 in the control group), of whom 370 (56%) came from the
HSV-039 efﬁcacy trial. For the 660 women  with at least one preg-
nancy reported in these studies, the mean age was 22.9 ± 5.4 years
in the HSV vaccine group and 23.1 ± 5.2 years in the control group
(age range: 13–45 years). Demographic characteristics for women
who reported at least one pregnancy, for each group, are reported
in Supplementary Table 1.
F. Tavares et al. / Vaccine 31 (2013) 1759– 1764 1761
Table 1
Number of women vaccinated and number of women  who  reported at least one pregnancy and the pregnancy outcomes of interest during the entire study period for selected
studies (total vaccinated cohort, females only).
GSK study ref (NCT) N ≥1 pregnancy (n) Spontaneous
abortion (n)
Elective abortion (n) Control producta Age range of study
population (years)
HSV-007 268 23 4 4 AS04 18–45
HSV-016 (00698568) 4095 90 8 13 Placeboc ≥18
HSV-017 (00699764) 1086 90 8 8 Placeboc 18–45
HSV-039 (00057330) 8323 370 50 85 HAV 18–30
HSV-040 (00224484) 5955 87 11 37 HAV or Placeboc 10–17
Total 19,727b 660 81 147 – 10–80
AS04, adjuvant system; HAV, Hepatitis A vaccine; N, number of women  who received at least one vaccine dose during the study.
a The investigational product in all studies was  the gD HSV vaccine.
b HSV group: 10,964 women; control group: 8763 women.
c Placebo was  represented by: aluminum (500 g aluminum hydroxide), 2-phenoxyethanol as preservative in studies HSV-016 and HSV-017 and saline solution in study
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.3. Pregnancy outcomes
Of the 660 ﬁrst pregnancies (368 in the HSV vaccine group and
92 in the control group), 49 (13.3%) in the HSV vaccine group and
2 (11%) in the control group resulted in spontaneous abortion;
9 (24.2%) and 58 (20%), respectively, resulted in elective abortion
Table 2).Of the completed pregnancies reported, 205 in the HSV vaccine
roup and 169 in the control group resulted in the birth of chil-
ren with no apparent congenital anomaly (Table 3). Congenital
nomaly, ectopic pregnancy or still births were each reported for
able 2
verall and subgroup analyses of pregnancy outcomes of interest in the HSV group and c
HSV vaccine
Spontaneous abortion Elective 
No. of
pregnancies
(N)
n (%) No. of
pregnan
(N)
Adverse pregnancy outcomes of interest
Overall 368 49 (13.3) 368 
Within the vaccination exposure window 96 16 (16.7) 96 
Pregnancy outcomes by gestational age (weeks)
Overall
0–8  49 33 (80.5) 89 
9–12  49 7 (17.1) 89 
13–20  49 1 (2.4) 89 
≥20  49 0 89 
Unknown 49 8 89 
Within risk window
0–8 16 15 (93.8) 37 
9–12  16 1 (6.3) 37 
13–20  16 0 37 
≥20  16 0 37 
Unknown 16 0 37 
Pregnancy outcomes by vaccine doses received before pregnancy onset
Overall
1  49 1 (2.5) 89 
2  49 11 (27.5) 89 
3  49 28 (70.0) 89 
4  49 0 89 
Unknown 49 9 89 
Within risk window
1 16 1 (7.1) 37 
2  16 7 (50.0) 37 
3  16 6 (42.9) 37 
4  16 0 37 
Unknown 16 2 37 
, total number of pregnant women vaccinated in a given category; n, number of subjec
ategory, with available results ×100; RR, relative risk, 95%CI for RR (exact stratiﬁed cond
o  number of cases.0–4 pregnancies in each group. Twenty-three and 28 pregnancies
from the HSV vaccine and control groups were lost to follow-up or
with unknown outcome (Table 3).
Spontaneous and elective abortions occurred most frequently
during the ﬁrst 8 weeks of gestation for both groups, regardless
of the timing of vaccination (Table 2). When considering all preg-
nancies, the highest proportion of pregnancy outcomes of interest
occurred in women  who received 3 vaccine doses in both the HSV
vaccine and control groups. For pregnancies with onset during
the vaccination exposure window the highest pregnancy outcomes
occurred after 2 vaccine doses (Table 2).
ontrol group.
Control group
abortion Spontaneous abortion Elective abortion
cies
n (%) Total No. of
pregnancies
(N)
n (%) Total No. of
pregnancies
(N)
n (%)
89 (24.2) 292 32 (11.0) 292 58 (20.0)
37 (38.5) 84 8 (9.5) 84 28 (33.3)
47 (72.3) 32 19 (73.1) 58 42 (89.4)
13 (20.0) 32 6 (23.1) 58 4 (8.5)
3 (4.6) 32 1 (3.8) 58 1 (2.1)
2 (3.1) 32 0 58 0
24 32 6 58 11
26 (70.3) 8 6 (75.0) 28 24 (88.9)
7 (18.9) 8 2 (25.0) 28 3 (11.1)
3 (8.1) 8 0 28 0
1 (2.7) 8 0 28 0
0 8 0 28 1
8(12.3) 32 4 (15.4) 58 8 (17.4)
22 (33.8) 32 5 (19.2) 58 17 (37.0)
34 (52.3) 32 16 (61.5) 58 20 (43.5)
1 (1.5) 32 1 (3.8) 58 1 (2.2)
24 32 6 58 12
7(20.6) 8 2 (25.0) 28 8 (32.0)
20 (58.5) 8 4 (50.0) 28 13 (52.0)
7 (20.6) 8 2 (25.0) 28 3 (12.0)
0 8 0 28 1 (4.0)
3 8 0 28 3
ts with the pregnancy outcome; %, n/number of pregnancies in women  in a given
itional to total number of cases), p-value = 2-sided exact stratiﬁed test conditional
1762 F. Tavares et al. / Vaccine 31 (2013) 1759– 1764
Table 3
Percentage of women  with pregnancy and pregnancy outcomes (total vaccinated cohort, women only, pooled data).
HSV
N = 10,964
Control
N = 8763
n % n %
At least one pregnancy reported 368 3.4 292 3.3
Spontaneous abortion 49 0.4 32 0.4
Elective termination 89 0.8 58 0.7
Other  outcome 230 2.1 202 2.3
Live  birth with no apparent congenital anomaly 205 1.9 169 1.9
Live  birth with congenital anomaly 0 <0.1 4 <0.1
Ectopic pregnancy 1 <0.1 0 <0.1
Still  birth 1 <0.1 1 <0.1
N ; n/%, 
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exposure window. This observation could be explained by the vac-
cination schedule used in HSV studies: doses 1 and 2 were given
one month apart and dose 3 was administered 5 months after dose
Fig. 1. Relative risk for completed pregnancies with onset within the vaccinationLost  to follow-up/unknown 23
, total number of women  who received at least one vaccine dose during the study
.4. Evaluation of the primary and secondary endpoints:
utcomes associated with pregnancies conceived during the
accination exposure window
In the HSV vaccine group, 96 pregnancies had an onset within
he vaccination exposure window, of which 16 (16.7%) resulted
n spontaneous abortion and 37 (38.5%) resulted in elective abor-
ion (Supplementary Table 2). Among the 84 pregnancies in the
ontrol group with onset within the vaccination window, 8 (9.5%)
esulted in spontaneous abortion and 28 (33.3%) in elective abor-
ion (Supplementary Table 2).
For completed pregnancies (i.e. pregnancies with known out-
ome) with onset within the vaccination exposure window, the
alculated RR for spontaneous abortion for HSV vaccine groups rel-
tive to the control groups was 1.7 (95% CI: 0.7–4.6) and that for
lective abortion was 1.2 (95% CI: 0.7–2.0) (Fig. 1A). Fig. 2A shows
he contribution of each study on the assessment of the RR for
pontaneous abortion with pregnancy onset within the vaccination
xposure window.
For all completed pregnancies, the RR for spontaneous abortion
n the HSV vaccine group as compared to the control group was
.3 (95% CI: 0.8–2.1); for elective abortion the RR was  1.3 (95% CIs:
.9–1.8) (Fig. 1B). Fig. 2B shows the contribution of each study in
he assessment of the overall RR for spontaneous abortion for all
ompleted pregnancies.
. Discussion
We describe the results of a meta-analysis performed to eval-
ate the RR of adverse pregnancy outcomes in women exposed to
n AS04-adjuvanted HSV glycoprotein D genital herpes candidate
accine or control, in studies conducted as part of a clinical vaccine
evelopment program.
Among women with a ﬁrst pregnancy during the vaccination
xposure window spontaneous abortion was more frequent in the
SV vaccine group: of 96 reported pregnancies 16 resulted in spon-
aneous abortions (16.7%). In the control group of 84 reported
regnancies 8 resulted in spontaneous abortions (9.5%). When all
omen who reported at least one pregnancy were included in
he analysis, the proportions were 13.3% in HSV vaccinees (of 368
eported pregnancies, 49 resulted in spontaneous abortions) and
1% in the control groups (of 292 reported pregnancies, 32 resulted
n spontaneous abortions). Just over half of the pregnancies ana-
yzed were accounted for by a single study, the HSV-039 study. The
R for the primary and secondary endpoints of the meta-analysis
ere 1.7 (95% CI: 0.7–4.6) and 1.2 (95% CI: 0.7–1.9) with conﬁdencentervals including 1.
Rates of spontaneous abortion reported in the literature for clin-
cally recognized pregnancies (i.e. having reached at least four to
ve gestational weeks after LMP) up to 28 weeks of gestation vary0.2 28 0.3
number/percentage of women in a given category.
from 11% to 16.0% [9,10,14,16,22,21,24],  which are in the same
range as the rates described in the present meta-analysis.
We  did not identify a dose–response for developing adverse
pregnancy outcomes. The proportions of pregnancy outcomes of
interest were highest after 3 vaccine doses in both HSV and control
groups, when considering all pregnancies, and after 2 vaccine doses
when considering pregnancies with onset during the vaccinationexposure window (Panel A) and for all completed pregnancies (Panel B), classiﬁed
by  pregnancy outcome of interest. Notes: ‘Other outcomes’ refers to ectopic preg-
nancy, live infant with congenital anomaly, live infant with no apparent congenital
anomaly, lost to follow up/unknown or stillbirth. RR, relative risk; CI, conﬁdence
interval.
F. Tavares et al. / Vaccine 3
Fig. 2. Forest plot of relative risk of spontaneous abortions for completed preg-
nancies with onset within the vaccination exposure window (Panel A) and for all
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completed pregnancies (Panel B). Note: In the HSV-007 study, 4 spontaneous abor-
ions were reported, none of which were associated with the vaccination exposure
indow. This study was  not included in the Panel A of the ﬁgure.
, which provides a long reporting period after dose 2. Additionally,
he proportion of spontaneous abortions in this meta-analysis was
ighest early in pregnancy (during the ﬁrst 8 weeks of gestation),
ith a substantial decrease after 8–12 weeks. This is consistent with
he expected distribution of spontaneous abortions in the general
opulation [22,23].
There are some limitations to this meta-analysis. Pregnancy is
lassically an exclusion criterion for participation in vaccine clinical
rials. The HSV trials included in this meta-analysis enrolled either
omen of childbearing potential, who had a negative pregnancy
est at enrollment and prior to each vaccination and who  used an
ccepted method of birth control, or women of non-childbearing
otential. Among a large number of women in the trials selected
ere (19,727 women vaccinated), 660 reported at least one preg-
ancy during the conduct of the study, and of these, 180 became
regnant during the vaccination exposure window (i.e. a suscep-
ible period for spontaneous abortion). Although almost nothing
s known about the time-window during which the likelihood of
regnancy loss would be highest if there would be a potential
accine-related effect, one may  assume that this period would be
lose to vaccination, the period when one may  expect unintended
regnancies to occur in these clinical trials. An unintended vac-
ination earlier during pregnancy is an important issue, as the
robability of loss is much higher earlier in gestation, thus it may
alsely increase the risk of adverse outcomes in the vaccinated
ohort. Several authors have reported some bias in analyses of1 (2013) 1759– 1764 1763
spontaneous abortion rates, for example the underreporting of
elective abortions in countries in which abortion is prohibited
[7,11,17]. Misreporting elective abortions as spontaneous abortions
(by women in either group) could also falsely increase the rate of
spontaneous abortions in the subset of women  who  conceived close
to vaccination. It is reassuring that despite these potential sources
of bias against the vaccinated cohort, no safety signal was detected.
Other limitations of this analysis include the variability between the
studies in terms of demographic characteristics of the study pop-
ulation (e.g. age, socioeconomic status and obstetric history), and
duration of follow-up. Additionally, it was not possible to adjust
the analysis for confounders or risk factors (e.g. older maternal age,
assisted conception, low pre-pregnancy body mass index, regular
or high alcohol consumption, older paternal age, previous repro-
ductive history, thyroid abnormalities, diabetes, congenital uterine
abnormalities and smoking). Finally, a clear limitation of the study
is that over half of the cases came from one study.
Concerns about the risk of vaccination on pregnancy outcome
are considered to be primarily theoretical [13]. Indeed, certain vac-
cinations during pregnancy are either recommended (e.g. ﬂu) or
common practice. Any theoretical concern on a possible role of an
adjuvant or adjuvant system, including AS04, should consider the
mechanism of action of the adjuvant and its impact on the innate
immune response. AS04 transiently induces local NF-B activity
and cytokine production. This leads to an increased number of acti-
vated antigen-loaded dendritic cells and monocytes in the lymph
node draining the injection site, which further increase the activa-
tion of antigen-speciﬁc T cells [5].  Therefore, since the effect of AS04
after the intramuscular injection is local, not systemic, and time-
limited [5],  any effect on the course of a pregnancy is unlikely. Safety
data from studies evaluating other vaccine formulations contain-
ing AS04 conﬁrm this. In the development program of a HPV-16/-18
AS04-adjuvanted vaccine; CervarixTM, GlaxoSmithKline Vaccines),
a numerical imbalance in spontaneous abortions was noted in a
large phase III trial which included women of childbearing poten-
tial [15]. This initial observation triggered the pooled analysis of
2 randomized controlled trials (Papilloma TRIal Against Cancer In
young Adults (PATRICIA) [15] and The Costa Rica Vaccine Trial [12])
aiming to evaluate the risk of spontaneous abortion based on data
from both trials [20]. Eligible women  aged between 15 and 25 years
received either the HPV-16/-18 adjuvanted vaccine or the con-
trol hepatitis A vaccine. Spontaneous abortion was diagnosed by
self-report and clinical judgment of the investigator; or a positive
pregnancy test followed by a negative result. This analysis con-
cluded that there was  no overall effect of the HPV vaccine on risk
of spontaneous abortion (11.5% in HPV vaccine group and 10.2% in
HAV vaccine group). A small numerical difference in spontaneous
abortion rates between arms in the subset of pregnant women  who
conceived closer to vaccination was  reported with the HPV-16/-18
vaccine (13.7% in HPV vaccine group compared with 9.2% in HAV
vaccine group) [20]. However, a statistical analysis by permutation
test (aiming to account for potential effect of timing of vaccination
relative to time of conception) found that the rate of spontaneous
abortion in women who conceived within 3 months after receiving
the HPV study vaccine was  not signiﬁcantly higher than in women
assigned to a control arm [20]. To date, studies assessing safety of
vaccines that contain AS04 have consistently demonstrated clin-
ically acceptable safety proﬁles [1,2,4,8,19].  Previously reported
pharmacovigilance data for other adjuvanted vaccines that are
administered during pregnancy also show no sign of unusual or
severe adverse events for either the mother or the fetus [18,25].
This meta-analysis showed that the RR of spontaneous abortions
and elective abortions for patients inadvertently exposed to HSV
vaccination were not signiﬁcantly increased. Women of childbear-
ing age are a major target group for vaccine trials, not only for HSV
vaccines but for any trial assessing prophylactic vaccines against
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otential sexually transmitted diseases. It is therefore essential to
ontinue to monitor the safety of vaccines intended for women  of
hildbearing age in terms of pregnancy outcomes.
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